PE-A 5% will be performed using 5% albumin (Albutein 5%) as the main replacement fluid administered intravenously.

Standard medical treatment (SMT) will be administered according to institution standards.

Acute-On-Chronic Liver Failure

Plasma exchange treatment (PE-A 5%) will be performed using 5% albumin solution (Albutein 5%). Fresh frozen plasma will be given to prevent coagulopathy. IVIGs will be administered intravenously to prevent the development of hypogammaglobulinemia and infection.

SMT + PE-A 5%

Standard medical treatment according to the institution's standard practice

Standard Medical Treatment

Mayo Clinic Phoenix

Southern California Research Center

Emory University

University of Kansas

Rutgers-New Jersey Medical School

Mayo Clinic Rochester

Ohio State University Wexner Medical Center

University of Pennsylvania

University of Pittsburgh Medical Center

McGuire VA Medical Center

Aurora Health Care, Inc.

Medical University of Vienna

Université libre de Bruxelles

UZ Leuven - Campus Gasthuisberg

Rigshospitalet

Hôpital Beaujon

Centre Hépato-Biliaire - Hôpital Universitaire Paul Brousse

Universitätsklinikum Bonn

Universitätsklinikum Frankfurt

Hannover Medical School

Universitaetsklinikum Leipzig

Klinikum der Universitaet Muenchen

ASST Papa Giovanni XXIII

ASST Grande Ospedale Metropolitano Niguarda

Azienda Ospedaliera di Padova

Centro Hospitalar Lisboa Norte

Centro Hospitalar do Porto

Hospital Universitario del Valle Hebron

Hospital Clínic de Barcelona

Hospital General Gregorio Marañón

Hospital Universitario Ramón y Cajal

King's College Hospital NHS Foundation Trust

Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%

Effects of Plasma Exchange With Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects With "Acute-On-Chronic Liver Failure" (ACLF) at High Risk of Hospital Mortality

Time to death through Day 90 after randomization of SMT+PE-A 5% versus SMT alone

Time to transplant or death through Day 90 after randomization of SMT+PE-A 5% versus SMT alone

Time to death through Day 28 after randomization of SMT+PE-A 5% versus SMT alone

Grifols Therapeutics LLC

Instituto Grifols, S.A.

agammaglobulinemia

albumin

agammaglobulinemia/albumin

Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%

Najkompletnija baza ljekovitog bilja potpomognuta znanošću